A Phase 3 interventional study of bupivacaine liposome injectable suspension and Placebo in Pain, sponsored by Pacira Pharmaceuticals, Inc. Completed at 17 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-01.
Sponsored by Pacira Pharmaceuticals, Inc · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing Liposomal Bupivacaine in Pain — 5 open to participants now, 5 under way, 2 of them phase 3. Liposomal Bupivacaine · Pain.
Among the 36 studies testing Liposomal Bupivacaine in Pain, this one is the 2nd largest by enrollment, is one of 3 that started in 2016, is one of 6 in phase 3, and was the 20th registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →5 of the 36 studies testing Liposomal Bupivacaine in Pain are open now, in 2 countries. Recruiting first, the newest first:
Children's Hospital of Orange County · Sites in United States
Ages 7–17 · Healthy volunteers
Jessyka Lighthall · Sites in United States
Ages 18–99 · Healthy volunteers
Rutgers, The State University of New Jersey · Sites in United States
Ages 18+
Wake Forest University Health Sciences · Sites in United States
Ages 18+
Tongliao City People's Hospital · Sites in China
Ages 18–60
By country, each count listing its studies:
Liposomal Bupivacaine: first FDA approval 2011 (EXPAREL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 8 · Phase 4 22
First in 2013; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 232 is above the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 60 across the 36 interventional studies. Of the 24 that completed or were terminated, 21 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 36 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pacira Pharmaceuticals, Inc, one of the names counted as Pacira BioSciences, Inc.. Under that name alone:
Pacira Pharmaceuticals, Inc is the lead sponsor of 102 studies on the registry; 3 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 17 (65%) have results posted.
29 studies in Pain by Pacira BioSciences, Inc.: none open now, none under way, none of them phase 3. Of 29 finished, 26 (90%) have results posted.
Among the 29 studies in Pain by Pacira BioSciences, Inc., this one is the 4th largest by enrollment, is one of 4 that started in 2016, is one of 8 in phase 3, and was the 20th registered.
Pacira BioSciences, Inc.’s Pain studies by the year they started, since 2007.
4 of the studies testing Liposomal Bupivacaine in Pain that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05964868Phase 3Jessyka LighthallEfficacy of Liposomal Bupivacaine Post Septorhinoplasty | 2026-12 |
| NCT06077422Phase 3Rutgers, The State University of New JerseyExparel vs. Marcaine ESP Block for Post-cardiac Surgical Pain | 2027-01-11 |
| NCT07097493Wake Forest University Health SciencesLiposomal Bupivacaine vs Perineural Adjuvants in Adductor Canalf and iPACK Blocks in Total Knee Arthroplasty | 2027-06 |
| NCT07795203Tongliao City People's HospitalLiposomal Bupivacaine vs Ropivacaine for Post-hemorrhoidectomy Analgesia | 2027-09-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 36 studies testing Liposomal Bupivacaine in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pacira BioSciences, Inc.’s 29 in Pain:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study in 232 adult subjects undergoing primary unilateral TKA under general or spinal anesthesia.
On Day 0, eligible subjects will be randomized in a 1:1:1 ratio to receive a single dose of either EXPAREL 133 mg in 10 mL expanded in volume with 10 mL of normal saline for a total volume of 20 mL (Group 1); EXPAREL 266 mg in 20 mL (Group 2); or placebo 20 mL (Group 3). Study drug (EXPAREL or placebo) will be administered in a blinded manner via an ultrasound guided single-dose femoral nerve block at least 1 hour prior to surgery. Prior to placement of the prosthesis, 8 mL of bupivacaine hydrochloride (HCl) (0.5%) diluted with 8 mL of normal saline will be administered by the surgeon as a periarticular infiltration to the posterior capsule (8 mL medially and 8 mL laterally).
Postsurgical assessments will include pain intensity scores using a 10-cm visual analog scale (VAS); total postsurgical opioid consumption; overall benefit of analgesia score (OBAS) questionnaire; subject satisfaction with overall analgesia using a 5-point Likert scale; neurological assessment; sensory function assessment; motor function assessment; the study physical therapy assessments (ie, timed walk, timed up and go, and stair climbing tests); discharge readiness; unscheduled phone calls or office visits related to pain; 12-lead ECGs; vital sign measurements; and clinical laboratory tests. Adverse events will be recorded from the time the informed consent form (ICF) is signed through postsurgical Day 29.
Follow-up visits will be scheduled for all subjects on postsurgical Days 6 and 10. A follow-up phone call will be made on postsurgical Day 29.
Pharmacokinetic (PK) parameters will be estimated from plasma bupivacaine measurements using non-compartmental analysis based on the sampling schedule of baseline (prior to the nerve block) through postsurgical Day 10.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single dose of 133 mg (10 mL) EXPAREL (bupivacaine liposome injectable suspension) expanded in volume with 10 mL of normal saline for a total volume of 20 mL.
Drug: bupivacaine liposome injectable suspension
Single dose of 266 mg (20 mL) EXPAREL (bupivacaine liposome injectable suspension).
Drug: bupivacaine liposome injectable suspension
Normal saline (20 mL).
Drug: Placebo
bupivacaine liposome injectable suspension 133 mg expanded with normal saline to 20 mL or 266 mg in 20 mL
Also known as: EXPAREL
Normal saline.
Also known as: Normal saline
Area Under the Curve (AUC) of Visual Analog Scale (VAS) Pain Intensity Scores Through 72 Hours
AUC of VAS pain intensity scores through 72 hours. Visual Analog Scale (VAS) is a pain scale. The VAS was presented as a straight 10 cm line, where 0 cm is no pain and 10 cm is the worst pain possible. Patients were asked, "How much pain are you experiencing right now? Please place a vertical mark on the line below to indicate the level of pain you are experiencing right now."
Time frame: 0-72 hours
Total Postsurgical Opioid Consumption Through 72 Hours
Total postsurgical opioid consumption (converted to IV morphine equivalents) through 72 hours
Time frame: 0-72 hours
Percentage of Opioid-free Participants Through 72 Hours
Percentage of participants who did not receive opioid medication through 72 hours
Time frame: 0-72 hours
Time to First Opioid Rescue Through 72 Hours
Time to first opioid rescue medication consumed through 72 hours. The "time to rescue" is estimated for each quartile from the Kaplan-Meier analysis, in which first quartile represents the time it took for the first 25% of the population to receive rescue medication, median quartile represents the time it took 50% of the population to receive rescue medication, and third quartile represents the time it took 75% of the population to receive rescue medication.
Time frame: 0-72 hours
Participants were recruited between June 3, 2016 and June 30, 2017 at 13 sites in the US and Europe
| Milestone | EXPAREL 133 mg | EXPAREL 266 mg | Placebo |
|---|---|---|---|
| Started | 76 | 77 | 79 |
| Completed | 75 | 73 | 74 |
| Not completed | 1 | 4 | 5 |
AUC of VAS pain intensity scores through 72 hours. Visual Analog Scale (VAS) is a pain scale. The VAS was presented as a straight 10 cm line, where 0 cm is no pain and 10 cm is the worst pain possible. Patients were asked, "How much pain are you experiencing right now? Please place a vertical mark on the line below to indicate the level of pain you are experiencing right now."
| cm*hr | EXPAREL 133 mg | EXPAREL 266 mg | Placebo |
|---|---|---|---|
| Area Under the Curve (AUC) of Visual Analog Scale (VAS) Pain Intensity Scores Through 72 Hours | 259.545 ± 19.011 | 250.998 ± 18.849 | 279.794 ± 18.493 |
Total postsurgical opioid consumption (converted to IV morphine equivalents) through 72 hours
| mg | EXPAREL 133 mg | EXPAREL 266 mg | Placebo |
|---|---|---|---|
| Total Postsurgical Opioid Consumption Through 72 Hours | 69.466 ± 4.403 | 74.393 ± 4.669 | 81.469 ± 5.006 |
Percentage of participants who did not receive opioid medication through 72 hours
| Participants | EXPAREL 133 mg | EXPAREL 266 mg | Placebo |
|---|---|---|---|
| Percentage of Opioid-free Participants Through 72 Hours | 0 | 0 | 0 |
Time to first opioid rescue medication consumed through 72 hours. The "time to rescue" is estimated for each quartile from the Kaplan-Meier analysis, in which first quartile represents the time it took for the first 25% of the population to receive rescue medication, median quartile represents the time it took 50% of the population to receive rescue medication, and third quartile represents the time it took 75% of the population to receive rescue medication.
| h | EXPAREL 133 mg | EXPAREL 266 mg | Placebo |
|---|---|---|---|
| First quartile | 1.80 (0.87 to 2.22) | 1.53 (0.75 to 2.13) | 1.08 (0.65 to 1.65) |
| Second quartile | 3.03 (2.38 to 3.85) | 2.87 (2.25 to 3.47) | 2.40 (1.68 to 2.90) |
| Third quartile | 5.07 (4.15 to 7.25) | 5.78 (3.98 to 8.12) | 3.72 (3.15 to 5.07) |
Collected over From screening to day 29 postsurgery. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| EXPAREL 133 mg | 0/75 (0%) | 5/75 (6.7%) | 73/75 (97.3%) |
| EXPAREL 266 mg | 0/76 (0%) | 8/76 (10.5%) | 74/76 (97.4%) |
| Placebo | 0/79 (0%) | 6/79 (7.6%) | 76/79 (96.2%) |
| Event | EXPAREL 133 mg | EXPAREL 266 mg | Placebo |
|---|---|---|---|
| Postprocedural hematomaInjury, poisoning and procedural complications | 3/75 | 1/76 | 0/79 |
| Motor dysfunctionNervous system disorders | 0/75 | 2/76 | 0/79 |
| Atrial fibrillationCardiac disorders | 1/75 | 1/76 | 1/79 |
| Postprocedural swellingInjury, poisoning and procedural complications | 1/75 | 0/76 | 0/79 |
| CellulitisInfections and infestations | 1/75 | 0/76 | 0/79 |
| Sinus bradycardiaCardiac disorders | 0/75 | 1/76 | 0/79 |
| Transient ischemic attackNervous system disorders | 0/75 | 1/76 | 0/79 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/75 | 1/76 | 0/79 |
| Anaphylactic shockImmune system disorders | 0/75 | 1/76 | 0/79 |
| BradycardiaCardiac disorders | 0/75 | 0/76 | 1/79 |
| Event | EXPAREL 133 mg | EXPAREL 266 mg | Placebo |
|---|---|---|---|
| Motor dysfunctionNervous system disorders | 34/75 | 35/76 | 34/79 |
| NauseaGastrointestinal disorders | 27/75 | 34/76 | 24/79 |
| PyrexiaGeneral disorders | 23/75 | 18/76 | 22/79 |
| ConstipationGastrointestinal disorders | 12/75 | 16/76 | 15/79 |
| VomitingGastrointestinal disorders | 4/75 | 10/76 | 9/79 |
| Urinary retentionRenal and urinary disorders | 3/75 | 10/76 | 8/79 |
| PruritusSkin and subcutaneous tissue disorders | 4/75 | 8/76 | 10/79 |
| HypotensionVascular disorders | 8/75 | 4/76 | 5/79 |
| Hepatic enzyme increasedInvestigations | 7/75 | 1/76 | 3/79 |
| DizzinessNervous system disorders | 3/75 | 7/76 | 5/79 |
Safety population included all participants who received study drug, with analysis by actual treatment received.
| Age, Continuous(years) | EXPAREL 133 mg | EXPAREL 266 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 64.6 ± 6.94 | 66.0 ± 9.01 | 65.4 ± 8.69 | 65.3 ± 8.26 |
| Sex: Female, Male(Participants) | EXPAREL 133 mg | EXPAREL 266 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 36 | 43 | 53 | 132 |
| Male | 39 | 33 | 26 | 98 |
| Ethnicity (NIH/OMB)(Participants) | EXPAREL 133 mg | EXPAREL 266 mg | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 2 | 2 | 2 | 6 |
| Not Hispanic or Latino | 73 | 74 | 75 | 222 |
| Unknown or Not Reported | 0 | 0 | 2 | 2 |
| Race (NIH/OMB)(Participants) | EXPAREL 133 mg | EXPAREL 266 mg | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 8 | 5 | 12 | 25 |
| White | 66 | 69 | 67 | 202 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 0 | 2 |
| Region of Enrollment(participants) | EXPAREL 133 mg | EXPAREL 266 mg | Placebo | Total |
|---|---|---|---|---|
| Belgium | 36 | 37 | 36 | 109 |
| United States | 38 | 38 | 40 | 116 |
| Denmark | 1 | 1 | 3 | 5 |
| Visual analog scale pain score(cm) | EXPAREL 133 mg | EXPAREL 266 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 2.12 ± 2.656 | 2.08 ± 2.546 | 1.80 ± 2.195 | 1.99 ± 2.458 |
| American Society of Anesthesiologists classification(Participants) | EXPAREL 133 mg | EXPAREL 266 mg | Placebo | Total |
|---|---|---|---|---|
| Score: 1 | 11 | 9 | 10 | 30 |
| Score: 2 | 41 | 41 | 46 | 128 |
| Score: 3 | 23 | 26 | 23 | 72 |
| Score: Greater than or equal to 4 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
The record gives a start of Jun 2016, a primary completion of Jun 2017 and a completion of Jun 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2020, 3 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liposomal Bupivacaine